NextCure (NASDAQ:NXTC) Trading Down 7.9%

NextCure, Inc. (NASDAQ:NXTC)’s stock price was down 7.9% during mid-day trading on Wednesday . The stock traded as low as $1.47 and last traded at $1.51. Approximately 116,132 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 243,919 shares. The stock had previously closed at $1.64.

Analysts Set New Price Targets

Several research analysts have issued reports on NXTC shares. HC Wainwright raised their target price on NextCure from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Needham & Company LLC reissued a “buy” rating and issued a $4.00 target price on shares of NextCure in a research report on Wednesday, March 20th.

NextCure Trading Up 1.9 %

The company has a 50-day moving average price of $1.73 and a two-hundred day moving average price of $1.39.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. On average, analysts forecast that NextCure, Inc. will post -1.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NXTC. Virtu Financial LLC purchased a new stake in shares of NextCure in the fourth quarter worth about $28,000. Jane Street Group LLC acquired a new stake in shares of NextCure in the fourth quarter valued at approximately $33,000. Cubist Systematic Strategies LLC acquired a new stake in shares of NextCure in the third quarter valued at approximately $33,000. Tower Research Capital LLC TRC increased its stake in NextCure by 100.5% during the third quarter. Tower Research Capital LLC TRC now owns 16,375 shares of the company’s stock worth $45,000 after acquiring an additional 8,206 shares during the last quarter. Finally, UBS Group AG increased its stake in NextCure by 224.6% during the first quarter. UBS Group AG now owns 9,160 shares of the company’s stock worth $45,000 after acquiring an additional 6,338 shares during the last quarter. 42.65% of the stock is owned by institutional investors and hedge funds.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.